schizophrenia, Bristol Myers Squibb
Jefferies has recently raised Bristol-Myers Squibb Co (BMY) stock to Buy rating, as announced on December 16, 2024, according to Finviz. Earlier, on December 10, 2024, BofA Securities had resumed the ...
This was the stock's third consecutive day of losses.
Wedmont Private Capital grew its stake in shares of Bristol-Myers Squibb (NYSE:BMY – Free Report) by 29.5% during the 4th ...
Bristol-Myers Squibb Co (BMY) stock saw a modest uptick, ending the day at $55.74 which represents a slight increase of $0.38 or 0.69% from the prior close of $55.36. The stock opened at $55.5 and ...
Analyst David Risinger of Leerink Partners reiterated a Buy rating on Bristol-Myers Squibb (BMY – Research Report), retaining the price target ...
The stock's rise snapped a three-day losing streak.
Bristol Myers Squibb CEO Chris Boerner described his company's new drug, Cobenfy, which can be used to treat psychiatric disorders like schizophrenia. He said the treatment is effective but doesn ...
Legacy Private Trust Co. lifted its position in Bristol-Myers Squibb (NYSE:BMY – Free Report) by 3.3% during the 4th quarter, ...
Arsenal Biosciences announced that Bristol Myers Squibb has exercised its exclusive license option for ArsenalBio’s AB-4000 series, the lead collaboration program generated unde ...
Bristol Myers Squibb CEO Christopher Boerner said $1.5B in annual cost savings should be achieved by the end of the year.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback